{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:06:01Z","timestamp":1791173161313,"version":"4.1.0"},"reference-count":63,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"24","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2007,8,20]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To determine the efficacy and safety of single-agent sorafenib in patients with recurrent and\/or metastatic squamous cell carcinoma of the head and neck (SCCHN) and nasopharyngeal carcinoma (NPC). <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> In this single-arm phase II trial, oral continuous sorafenib was administered in 28-day cycles. Patients had \u2264 one line of chemotherapy for recurrent and\/or metastatic disease, Eastern Cooperative Oncology Group performance status of \u2264 2, and adequate organ function. At the end of stage 1, efficacy criteria for further accrual were not met, but the study was amended to enroll an additional five patients for paired tumor biopsies. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> Twenty-seven and 26 patients were eligible for toxicity and efficacy evaluations, respectively. One patient (3.7%; 95% CI, 0.1% to 19.0%) achieved a partial response. Disease stabilization was maintained in 10 patients (37.0%; 95% CI, 22.4% to 61.2%). The median time to progression was 1.8 months (95% CI, 1.6 to 3.4 months), and median overall survival time was 4.2 months (95% CI, 3.6 to 8.7 months). Sorafenib was well tolerated with few grade 3 and no grade 4 toxicities. Biomarker analysis of paired tumor samples before and after treatment with sorafenib revealed a decrease of pERK in all five patients, with a decrease in Ki67 in four patients, consistent with a disruption of ERK signaling. The antiapoptotic protein Mcl-1 was downregulated in four patients, and there was also evidence of antiangiogenic activity. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> Sorafenib was well tolerated and had modest anticancer activity comparable to monotherapy with other targeted agents in this group of patients. Further development in combination with radiation or other agents may be warranted. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2006.10.2871","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T22:23:29Z","timestamp":1187389409000},"page":"3766-3773","source":"Crossref","is-referenced-by-count":203,"title":["Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma"],"prefix":"10.1200","volume":"25","author":[{"given":"Christine","family":"Elser","sequence":"first","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian L.","family":"Siu","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Winquist","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Agulnik","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo F.","family":"Chin","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Francis","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Cheiken","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Elting","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"McNabola","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Wilkie","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Petrenciuc","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric X.","family":"Chen","sequence":"additional","affiliation":[{"name":"From the Princess Margaret Hospital, University Health Network; Bayer Inc, Toronto; London Health Sciences Centre, London, Ontario, Canada; and Bayer Health Care, Bayer Research Center, West Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3348"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.8.1245"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.057"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.2.257"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058906"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058703"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2005.02.014"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.036"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-04-0297"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1381"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1038\/nature04483"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.081"},{"key":"R13","unstructured":"Ruiz-Godoy RL, Garcia-Cuellar CM, Herrera Gonzalez NE, et al: Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J Exp Clin Cancer Res 25:73,2006-78,"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1007\/BF02893944"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.3109\/00016489409126025"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206705"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1038\/nature00766"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Yarbrough WG, Shores C, Witsell DL, et al: Ras mutations and expression in head and neck squamous cell carcinomas. Laryngoscope 104:1337,1994-1347,","DOI":"10.1288\/00005537-199411000-00005"},{"key":"R19","unstructured":"Hoa M, Davis SL, Ames SJ, et al: Amplification of wild-type K-ras promotes growth of head and neck squamous cell carcinoma. Cancer Res 62:7154,2002-7156,"},{"key":"R20","unstructured":"Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350,2002-7356,"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.10.1873"},{"key":"R22","unstructured":"Treatment for advanced kidney cancer. FDA Consum 40:3,2006,"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4577"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.287"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0420"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10307"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200401000-00029"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1111\/j.0959-9673.2005.00447.x"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.411"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2029"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800552"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Riva C, Lavieille JP, Reyt E, et al: Differential c-myc, c-jun, c-raf and p53 expression in squamous cell carcinoma of the head and neck: Implication in drug and radioresistance. Eur J Cancer B Oral Oncol 31B:384,1995-391,","DOI":"10.1016\/0964-1955(95)00045-3"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.051"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602999"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.075"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1247"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Abidoye OO, Cohen EE, Wong SJ, et al: A phase II study of lapatinib (GW572016) in recurrent\/metastatic (R\/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24:297s,2006,  (suppl, abstr 5568)","DOI":"10.1200\/jco.2006.24.18_suppl.5568"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Kim ES, Kies MS, Glisson BS, et al: Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic\/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 24:285s,2006,  (suppl, abstr 5521)","DOI":"10.1200\/jco.2006.24.18_suppl.5521"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.4646"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.501"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Rhoades CA, Kraut E, Schuller D, et al: Phase I and II study of OSI-774 and docetaxel in squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 22:498s,2004,  (suppl, abstr 5541)","DOI":"10.1200\/jco.2004.22.90140.5541"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.6547"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.147"},{"key":"R44","doi-asserted-by":"publisher","DOI":"10.1002\/hed.10235"},{"key":"R45","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200110000-00031"},{"key":"R46","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200012000-00017"},{"key":"R47","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-199905000-00024"},{"key":"R48","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1419::AID-CNCR1>3.0.CO;2-7"},{"key":"R49","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"R50","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"R51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.507"},{"key":"R52","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.516"},{"key":"R53","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20640"},{"key":"R56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.11.014"},{"key":"R57","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6723"},{"key":"R58","doi-asserted-by":"crossref","unstructured":"Dhanda R, Gondek K, Song J, et al: A comparison of quality of life and symptoms in kidney cancer patients receiving sorafenib versus placebo. J Clin Oncol 24:225s,2006,  (suppl, abstr 4534)","DOI":"10.1200\/jco.2006.24.18_suppl.4534"},{"key":"R59","doi-asserted-by":"crossref","unstructured":"Gondek K, Dhanda R, Simantov R, et al: Health-related quality of life measures in advanced non-small cell lung cancer patients receiving sorafenib. J Clin Oncol 24:673s,2006,  (suppl, abstr 17085)","DOI":"10.1200\/jco.2006.24.18_suppl.17085"},{"key":"R60","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2005.23.16_suppl.515"},{"key":"R61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.120"},{"key":"R62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.119"},{"key":"R63","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"R64","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.125.4.417"},{"key":"R65","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208841"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2006.10.2871","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T20:06:45Z","timestamp":1653509205000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2006.10.2871"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,20]]},"references-count":63,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2007,8,20]]}},"alternative-id":["10.1200\/JCO.2006.10.2871"],"URL":"https:\/\/doi.org\/10.1200\/jco.2006.10.2871","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,20]]}}}